Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on May 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 financial results for quarter ended March 31, 2026.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Full results and management commentary furnished in Exhibit 99.1
- Investor focus: cash position, R&D spending, pipeline progress, and funding runway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.